Axitinib as a third or further line of treatment in renal cancer: a single institution experience

BMC Urology

Table 3 Univariate analysis of Progression Free Survival

Variables	N	mPFS	95% CI	P value
Sex
Male	10	4267	0,000 - 11,085	0,936
Female	11	6267	3318 - 9216	0,936
Histology
Clear Cell	16	4267	2568 - 5965	0,227
Non Clear-Cell	5	8433	7360 - 9507	0,227
Heng Group
Good	5	3.5	2498 - 4502	0,027
Intermediate	13	6.567	1478 - 11,655
Poor	1	18.167	. .
Sites Of Metastasis (Baseline)				0,738
1	8	4467	1695 - 7239
2	6	3533	0,000 - 7214
3	5	3,6	2383 - 4817
Sites Of Metastasis (Axitinib)
1	4	3033	0,000- 8064	0,963
2	2	3,5	. .
3	12	4267	2796 - 5738
4	3	6333	6227–6440
Previous TKIs
< 2	11	4467	1158 - 7775	0,704
≥ 2	11	6267	3064 - 9469	0,704
Axitinib line of treatment
3	12	4467	0,000 - 9615	0,443
> 3	9	6267	0,423 - 12,110	0,443
Dose Reduction
Yes	5	8433	7360 - 9507	0,216
No	16	3,6	2163 - 5037	0,216
Type of previous treatment
TKI only	1	9866		0,183
TKI/IO	2	2,8
TKI/mTORi	19	6333	1524-3347

ISSN: 1471-2490